Corcept Therapeutics (CORT) Assets Average (2011 - 2026)

Corcept Therapeutics has reported Assets Average for 16 years, with the latest figure at $851.8 million in Q2 2026.

• Quarterly Assets Average rose 3.36% year-over-year to $851.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $851.8 million (up 3.36% YoY) and the FY2025 annual result came in at $838.6 million, up 14.71% from the prior year.
• Assets Average rose to $851.8 million in Q2 2026 per CORT's latest filing, from $825.8 million in the prior quarter.
• Over five years, Assets Average peaked at $851.8 million in Q2 2026 and troughed at $445.9 million in Q1 2022.
• A 5-year average of $678.6 million and a median of $662.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average decreased 20.66% in 2022, then soared 34.69% in 2023.
• Over 5 years, Assets Average stood at $558.3 million in 2022, then increased by 8.85% to $607.8 million in 2023, then surged by 33.67% to $812.4 million in 2024, then grew by 2.18% to $830.1 million in 2025, then gained by 2.61% to $851.8 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $851.8 million, $825.8 million, and $830.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.